ONCORAL PHARMA ApS: Financial statements 2024
CVR: 35481214
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ONCORAL PHARMA ApS (CVR 35481214) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -366,788 and a net result of DKK -4,057,834 compared with DKK -2,667,242 the year before. Equity in the 2024 report amounted to DKK -33,190,121. The company had 1 employee in the financial year.
- Gross Profit
- DKK -366,788
- Profit/Loss
- DKK -4,057,834
- Equity
- DKK -33,190,121
- Total Assets
- DKK 678,851
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -367 t. | -4.1 mio. | -33.2 mio. | 1 |
| 2023 | - | -996 t. | -2.7 mio. | -29.1 mio. | 1 |
| 2022 | - | -7.5 mio. | -9.2 mio. | -26.5 mio. | - |
| 2021 | - | -13.8 mio. | -11.8 mio. | -17.3 mio. | - |
| 2020 | - | -3.9 mio. | -3.5 mio. | -5.4 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ONCORAL PHARMA ApS has published its annual report for 2023. Gross profit came to DKK -996,227, and the net result was DKK -2,667,242.
About ONCORAL PHARMA ApS
ONCORAL PHARMA ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Magnus Olafsson Corfitzen. The company is owned by Ascelia Pharma AB. The company has 0 employees (2014). In 2025, the company reported a gross profit of DKK -1,617,542 and a net result of DKK -2,313,169 compared with DKK -4,057,834 the year before. Equity in the 2025 report amounted to DKK -35,503,290.